Side-by-side · Research reference
5-Amino-1MQvsGHRP-2
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft8/38 cited
BPhase 2Reviewed15/42 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
GHRP-2
Hexapeptide GHRP · Phase 2 (clinical diagnostic)
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
5-Amino-1MQ
GHRP-2
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002
Feedback intact?
—
Yes, with somatostatin feedback active
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
GHRP-2
Standard dose
100–200 mg / day oralNeelakantan 2018
Anecdotal community range; murine doses scaled.
100–300 mcg per injectionBowers 1990
Frequency
Once daily, fasted
1–3× per day
Lower / starter dose
50 mg / day
50 mcg per dose
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
Phase 2 + clinical diagnostic useBowers 1990
Duration
8–12 weeks per cycle
8–12 weeks on / 4 off (anecdotal)
Form
Oral capsule
—
Timing
Morning fasted preferred
Pre-sleep + fasted preferred
Reconstitution
—
Bacteriostatic water
04Side Effects & Safety
Parameter
5-Amino-1MQ
GHRP-2
GI symptoms
Mild nausea (anecdotal)
—
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
—
Cancer risk
Unclear — NNMT also studied in oncology contexts
Contraindicated in active malignancy
Pregnancy / OB
Avoid
Avoid
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Prolactin elevation
—
Mild but measurable
Hunger
—
Strong appetite increase
Injection site reaction
—
Mild erythema
IGF-1 elevation
—
Strong; monitor with chronic high-dose use
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
GHRP-2
- ·Active malignancy
- ·Pregnancy / breastfeeding
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
GHRP-2
- ·Untreated diabetes
05Administration Protocol
Parameter
5-Amino-1MQ
GHRP-2
1. Form
Oral capsule. No injection.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
2. Administration
Take with water, fasted preferred.
SQ — abdomen or thigh. Rotate sites.
3. Timing
Morning fasted.
Pre-sleep + fasted preferred.
4. Storage
Room temp ≤25 °C, dry place.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Caveat
Monitor B-vitamin status with chronic use.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
5-Amino-1MQ
— no documented stacks
GHRP-2
+ CJC-1295 (no DAC)
StrongGHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.
- GHRP-2
- 100–200 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- High-amplitude GH pulse, body composition